Barclays Maintains Underweight on Amgen, Lowers Price Target to $210
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould maintains an Underweight rating on Amgen (NASDAQ:AMGN) and has lowered the price target from $225 to $210.
July 11, 2023 | 10:23 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barclays has maintained an Underweight rating on Amgen and lowered the price target from $225 to $210.
The lowered price target by Barclays indicates a bearish outlook for Amgen. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100